Company news

Rocket Pharmaceuticals, Inc. news in 2022

Rocket Pharmaceuticals, Inc.'s news releases, calls and decks from 2022, newest first.

View company

Rocket Pharmaceuticals Provides Update on Anticipated Registration Path for RP-A501 in Danon Disease Following End-of-Phase 1 FDA Meeting

December 21, 2022

Rocket Pharmaceuticals Presents Positive Clinical Data from Fanconi Anemia, Pyruvate Kinase Deficiency and Severe Leukocyte Adhesion Deficiency-I Programs at the 64th American Society of Hematology (ASH) Annual Meeting

December 11, 2022

Rocket Pharmaceuticals Completes Acquisition of Renovacor

November 30, 2022

Rocket Pharmaceuticals to Present at the 5th Annual Evercore ISI HealthCONx Conference

November 20, 2022

Rocket Pharmaceuticals Reports Third Quarter 2022 Financial Results and Highlights Recent Progress

November 2, 2022

Rocket Pharmaceuticals Announces Presentations Highlighting AAV and Lentiviral Gene Therapies at Upcoming Scientific Congresses

November 2, 2022

Rocket Pharmaceuticals Announces Presentations Highlighting Lentiviral Gene Therapies at the 29th Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

October 11, 2022

Rocket Pharmaceuticals to Present at the 2022 Cell & Gene Meeting on the Mesa

October 9, 2022

Rocket Pharmaceuticals Announces Pricing of Public Offering of Common Stock

October 2, 2022

Rocket Pharmaceuticals Announces Positive Updates from Phase 1 Clinical Trial for RP-A501 in Danon Disease at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

September 29, 2022

Rocket Pharmaceuticals to Present at Chardan 6th Annual Genetic Medicines Conference

September 26, 2022

Rocket Pharmaceuticals to Acquire Renovacor, Extending Leadership in AAV-based Cardiac Gene Therapy

September 19, 2022

Rocket Pharmaceuticals to Present Updated Data from Phase 1 Danon Disease Trial for RP-A501 at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2022

September 15, 2022

Rocket Pharmaceuticals to Present at Morgan Stanley 20th Annual Global Healthcare Conference

September 5, 2022

Rocket Pharmaceuticals Reports Second Quarter 2022 Financial Results and Highlights Recent Progress

August 7, 2022

Rocket Pharmaceuticals Appoints Mayo Pujols as Chief Technical Officer and Strengthens Manufacturing Capabilities

July 26, 2022

Rocket Pharmaceuticals to Present at William Blair Biotech Focus Conference

July 7, 2022

Rocket Pharmaceuticals Presents Positive Top-line Data from Severe Leukocyte Adhesion Deficiency-I Program at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 18, 2022

Rocket Pharmaceuticals Presents Positive Clinical Data from Danon Disease, Fanconi Anemia and Pyruvate Kinase Deficiency Programs at the 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT)

May 15, 2022

Rocket Pharmaceuticals to Present at UBS Global Healthcare Conference

May 10, 2022

Rocket Pharmaceuticals Reports First Quarter 2022 Financial Results and Highlights Recent Progress

May 4, 2022

Rocket Pharmaceuticals to Present at the Bank of America Securities 2022 Global Healthcare Conference

April 26, 2022

Rocket Pharmaceuticals to Present at Upcoming Investor Conferences

March 28, 2022

Rocket Pharmaceuticals Appoints Fady Malik, M.D., Ph.D., to Board of Directors

March 13, 2022

Rocket Pharmaceuticals Appoints Jessie Yeung as Vice President of Investor Relations and Corporate Finance

March 7, 2022

Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial and Operational Results

February 23, 2022

Rocket Pharmaceuticals Announces Participation in 11th Annual SVB Leerink Global Healthcare Conference

February 9, 2022

Rocket Pharmaceuticals Highlights Anticipated 2022 Milestones Across Lentiviral and AAV Gene Therapy Clinical Programs

January 10, 2022

Rocket Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

January 3, 2022

Decks in 2022